Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Folate Testing Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentMutual of OmahaPolicy AHS-G2154

    Folate Testing

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS-G2154 alerts

    Get alerted when Policy AHS-G2154 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of serum folate, red blood cell folate, and folate receptor autoantibody testing. It applies to providers requesting these laboratory tests, subject to the individual's benefit coverage and applicable Medicare or Medicaid requirements.

    Policy Summary
    PayerMutual of Omaha
    PolicyFolate Testing
    Policy CodePolicy N/A
    Change TypeEvidence and guideline updateno coverage criteria changes
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionOrder serum folate with vitamin B12 when evaluating suspected folate deficiency, and do not use RBC folate or folate receptor autoantibody testing for covered indications.
    SourceLink
    POLICY UPDATE CHANGES

    The background, guidelines and recommendations, and evidence-based scientific references were updated.

    2Covered serum folate indications
    0Covered RBC folate indications
    0Covered folate receptor autoantibody situations
    2Procedure codes identified

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4
    BCSH folate testing indications
    0Coverage criteria modifications

    Coverage Criteria

    Covered serum folate testing

    Measurement of serum folate concentration meets coverage criteria when the serum test is being performed for either of the following indications.

    Qualifying indication

    • Anemia indication: The individual has megaloblastic or macrocytic anemia.
    • Bariatric procedure indication: The individual has undergone or is scheduled for a bariatric procedure.

      Qualifying procedures include Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion/duodenal switch.

    Not covered folate testing

    The following testing does not meet coverage criteria.

    Not covered testing

    • RBC folate: Measurement of RBC folate does not meet coverage criteria for any indication.
    • Folate receptor autoantibodies: Folate receptor autoantibody testing does not meet coverage criteria for any situation.

      Published scientific literature does not confirm that the testing is required and beneficial for diagnosis and treatment.

    Guideline-supported folate testing indications

    Guidelines identify folate testing in any of the following clinical situations.

    Guideline-supported indications for folate testing

    • Unexplained or macrocytic/megaloblastic anemia: The individual has unexplained anemia, macrocytic anemia, or megaloblastic anemia.
    • Alcohol use with liver disease: The individual has excess alcohol intake, especially with coexisting liver disease.
    • Exfoliative skin disease: The individual has exfoliative skin disease.
    • Post-gastric or bariatric surgery: The individual is status post gastric or bariatric surgery.

    Chronic kidney disease anemia evaluation

    For anemia in chronic kidney disease, consider folate testing as part of an expanded evaluation when initial testing does not identify the cause.

    Anemia in chronic kidney disease with unrevealing initial evaluation: The individual has anemia and chronic kidney disease, and initial tests do not reveal the cause; folate may be included in an expanded evaluation based on the clinical scenario.

    The recommendation is not graded.

    Cytopenia and myelodysplastic syndrome evaluation

    Folate testing may be part of the initial or differential evaluation in selected hematologic conditions.

    Cytopenia or myelodysplastic syndrome evaluation: Serum or RBC folate may be measured during the initial evaluation of cytopenias suspected to represent myelodysplastic syndromes, or as needed to rule out coexisting causes of anemia in myelodysplastic syndrome-related anemia.

    Serum folate testing does not meet coverage criteria when ordered for an indication other than megaloblastic or macrocytic anemia or when the individual has not undergone, and is not scheduled for, a qualifying bariatric procedure. Qualifying procedures include Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion/duodenal switch.

    RBC folate testing does not meet coverage criteria for any indication.

    Folate receptor autoantibody testing does not meet coverage criteria in any situation.

    Routine red cell folate testing is generally unnecessary because serum folate alone is sufficient in most cases. The 2021 BCSH guidance notes that red cell folate may be considered only when there is strong clinical suspicion of folate deficiency despite a normal serum folate result and vitamin B12 deficiency has been ruled out; however, this policy does not provide coverage for RBC folate testing.

    The 2021 BCSH guidance identifies pregnancy and hemolytic anemia—including autoimmune hemolysis, red cell membrane disorders, and hemoglobinopathies—as situations in which folate supplementation should occur without folate testing.

    Folate receptor autoantibody testing is not covered because the published scientific literature does not confirm that the test is required and beneficial for the diagnosis and treatment of an individual's illness.

    Applicable Procedure Codes

    Applicable CPT/HCPCS Procedure CodesCPT
    82746Folic acid; serum.
    82747Folic acid; RBC.

    Provider Action and Denial Guidance

    Denial Risk

    Serum folate: confirm a covered indication

    Do not order serum folate for indications other than megaloblastic or macrocytic anemia, or a qualifying completed or scheduled bariatric procedure. Requests outside these indications do not meet coverage criteria.

    Denial Risk

    RBC folate is not covered

    RBC folate testing does not meet coverage criteria for any indication. Use the covered serum folate testing method when the clinical indication meets policy criteria.

    Denial Risk

    Do not order folate receptor autoantibody testing

    Folate receptor autoantibody testing does not meet coverage criteria in any situation. Published scientific literature does not confirm that the testing is required and beneficial for diagnosis and treatment.

    Clinical Background

    Folate, or vitamin B9, supports one-carbon metabolism and nucleic acid biosynthesis and is involved in methionine and homocysteine metabolism. Folate is closely linked to vitamin B12. Folate deficiency can contribute to megaloblastic or macrocytic anemia, although it is generally treatable through dietary changes or folic acid supplementation. Bariatric procedures may reduce folate absorption and increase the risk of deficiency. Serum folate and RBC folate provide related information, but this policy identifies serum folate as the covered testing method for specified indications.

    Definitions

    Definitions
    ConditionMacrocytic anemia
    Defining featureAnemia with a high mean corpuscular volume and large red blood cells.
    Mean corpuscular volumeThe average volume of red blood cells in an individual.
    Definitions
    ConditionMegaloblastic anemia
    Relationship to macrocytic anemiaA specific type of macrocytic anemia.
    Underlying defectNucleic acid metabolic defects, including folate and/or vitamin B12 deficiency, cause nuclear-cytoplasmic dyssynchrony, reduced bone-marrow cell divisions, and nuclear abnormalities in myeloid and erythroid precursors.

    Covered Clinical Indications

    Megaloblastic or macrocytic anemia

    Serum folate concentration measurement meets coverage criteria for this indication.

    Megaloblastic or macrocytic anemia: The individual has megaloblastic or macrocytic anemia, and serum folate concentration is measured.

    Completed or scheduled bariatric procedure

    Serum folate concentration measurement meets coverage criteria when the procedure has been completed or is scheduled.

    Qualifying bariatric procedure: The individual has undergone or is scheduled for a qualifying bariatric procedure.

    Qualifying procedures include Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion/duodenal switch.

    Unexplained anemia, macrocytic anemia, or megaloblastic anemia

    The 2021 BCSH guideline lists this as an indication for folate testing.

    Testing Frequency and Monitoring

    Frequency Limits
    TestsSerum vitamin B12 and folic acid.
    Standard frequencyMeasure at least annually or when macrocytosis is present.
    Increased-risk patientsCloser surveillance may be appropriate for patients at increased risk, such as those with small-bowel disease or resection.
    Frequency Limits
    TestsFolate deficiency monitoring with vitamin B12.
    Clinical settingAfter radical cystectomy.
    Minimum frequency

    Ordering Requirements

    Note

    Pair folate and vitamin B12 testing

    Order folate and vitamin B12 testing together when evaluating suspected folate deficiency. If folate deficiency remains suspected despite a normal serum folate result, RBC folate may be undertaken only after vitamin B12 deficiency has been ruled out.

    • Test folate and vitamin B12 together.
    • For suspected folate deficiency with a normal serum folate result, rule out vitamin B12 deficiency before undertaking RBC folate testing.

    Not Covered Services

    The following testing is not covered: RBC folate testing for all indications, folate receptor autoantibody testing for all situations, and serum folate testing for indications not described as covered, including indications other than megaloblastic or macrocytic anemia or a qualifying completed or scheduled bariatric procedure.

    Policy Summary
    PayerMutual of Omaha
    PolicyFolate Testing
    Policy CodePolicy N/A
    Change TypeEvidence and guideline updateno coverage criteria changes
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionOrder serum folate with vitamin B12 when evaluating suspected folate deficiency, and do not use RBC folate or folate receptor autoantibody testing for covered indications.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Procedure CodesProvider Action and Denial GuidanceClinical BackgroundDefinitionsCovered Clinical IndicationsTesting Frequency and MonitoringOrdering RequirementsNot Covered Services
    Definitions
    DefinitionAutoantibodies directed against folate receptor alpha.
    Test descriptionFRAT® is a diagnostic blood test that screens for folate receptor autoantibodies.
    Policy treatmentFolate receptor autoantibody testing does not meet coverage criteria in any situation and is not covered.
    Unexplained or macrocytic/megaloblastic anemia: The individual has unexplained anemia, macrocytic anemia, or megaloblastic anemia.

    Excess alcohol intake, especially with coexisting liver disease

    The 2021 BCSH guideline lists this as an indication for folate testing.

    Excess alcohol intake with liver disease: The individual has excess alcohol intake, especially with coexisting liver disease.

    Exfoliative skin disease

    The 2021 BCSH guideline lists this as an indication for folate testing.

    Exfoliative skin disease: The individual has exfoliative skin disease.

    Post-gastric or bariatric surgery

    The 2021 BCSH guideline lists this as an indication for folate testing.

    Post-gastric or bariatric surgery: The individual is status post gastric or bariatric surgery.

    Inflammatory bowel disease with suspected vitamin B12 or folic acid deficiency, anemia, or macrocytosis

    ECCO supports serum vitamin B12 and folic acid measurement in inflammatory bowel disease when deficiency or anemia evaluation is clinically indicated.

    Inflammatory bowel disease evaluation: The individual has inflammatory bowel disease with suspected vitamin B12 or folic acid deficiency, anemia, or macrocytosis.

    Measure serum vitamin B12 and folic acid at least annually or when macrocytosis is present; closer surveillance may be appropriate for patients at increased risk, including those with small-bowel disease or resection.

    Newly diagnosed celiac disease or follow-up monitoring when folate was abnormal at baseline

    ACG supports folic acid assessment for newly diagnosed celiac disease and individualized follow-up when baseline testing was abnormal.

    Celiac disease testing context

    • New diagnosis: The individual has newly diagnosed celiac disease and is undergoing assessment for micronutrient deficiencies, including folic acid.
    • Follow-up monitoring: The individual is undergoing follow-up monitoring for celiac disease and folate was abnormal at baseline.

      Follow-up blood tests should be individualized to verify correction of previously abnormal results.

    Anemia in diabetes-associated chronic kidney disease

    AACE/ACE supports folate evaluation when anemia in diabetes-associated chronic kidney disease requires further investigation.

    Anemia requiring further investigation: The individual has diabetes-associated chronic kidney disease with anemia requiring further investigation, including folate evaluation.

    Folate may be evaluated with iron, transferrin saturation, ferritin, and vitamin B12 levels.

    Acute illness or critical illness after bariatric procedures or when micronutrient deficiency is suspected

    ASPEN/SSCM supports evaluation for folate deficiency in selected hospitalized or critically ill adults.

    Hospitalized or critically ill adult evaluation

    • Acute illness after bariatric procedure: The individual is acutely ill and hospitalized with a history of sleeve gastrectomy, gastric bypass, or biliopancreatic diversion with or without duodenal switch; evaluation for folate depletion is considered.
    • Critical illness with suspected micronutrient deficiency: The individual is critically ill and folate or another micronutrient deficiency is suspected; evaluation and treatment of folate deficiency may be considered.

    Nutritional anemia assessment in adult oncology patients

    The Academy of Nutrition and Dietetics includes folate in the nutritional anemia profile for adult oncology patients.

    Nutritional anemia assessment: The adult oncology patient is being evaluated for nutritional anemia and folate is included in the nutritional anemia profile.

    The profile includes hemoglobin, hematocrit, folate, vitamin B12, and iron.

    Anemia evaluation in chronic kidney disease

    The Renal Association recommends serum folate measurement for evaluation of anemia in chronic kidney disease.

    Anemia evaluation in chronic kidney disease: The individual has anemia in chronic kidney disease and serum folate concentration is measured as part of the evaluation.
    Monitor for vitamin B12 and folate deficiency at least annually.
    Frequency Limits
    Clinical settingPregnancy after bariatric surgery.
    Monitoring frequencyPerform nutritional surveillance laboratory screening each trimester for folate deficiency, along with iron, calcium, vitamin B12, and vitamin D.
    Malabsorptive proceduresConsider more extensive testing after malabsorptive procedures based on symptoms and risks; this may include fat-soluble vitamins, zinc, and copper.